We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.
Overview Our 2025/26 business plan reaffirms MHRA’s commitment to…
MHRA achievements and highlights for 2025/26 and key projections for 2026/2027.
MHRA transactions over £500 made using the government procurement card (GPC).
Information on how the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is controlling spend on branded medicines in the NHS.
A programme to help decision making across the lifecycle of products, benefitting both regulatory and health technology assessment (HTA) evaluations.
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Minutes of a meeting held between the government, NHS England and ABPI about the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
Annual review of the Health Service Products (Provision and Disclosure of Information) Regulations 2018 and the Health Service Medicines (Price Control Penalties and Price Control Appeals Amendment) Regulations 2018.
Information on how the 2019 voluntary scheme for branded medicines pricing and access (VPAS) controlled spend on branded medicines in the NHS between 2019 and 2023.
UKHSA and Porton Biopharma Limited have committed to being more transparent with the public about when, how and why we use animals in research.
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
MHRA annual report and accounts 2024 to 2025.
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency's strategic direction over the next three years.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).